Vitiligo Treatment Market size will be US$ 822.75 Million by 2028, according to the report. Vitiligo, a prevalent skin condition affecting around 70 million individuals globally, stems from the immune-triggered deterioration of melanocytes. The most prevalent subtype, non-segmental vitiligo, typically follows a chronic trajectory and often inflicts notable psychosocial ramifications on sufferers. Timely identification, awareness of associated conditions, accurate gauging of disease scope and intensity, scrutiny of quality-of-life impairments, and swift implementation of treatment grounded in current evidence-based practices are pivotal pillars in vitiligo management. Notably, 20-35% of patients are children. In July 2022, the FDA's green lighting of the 1.5% ruxolitinib cream marked a significant milestone as the first topical solution for non-segmental vitiligo in individuals aged 12 and above, providing gratifying results for dedicated vitiligo advocates.
Ongoing research delves into vitiligo's origins and novel treatments, advancing the market. Advocacy groups support companies, offering resources and improving accessibility. Technological advancements, like lasers and drug delivery, enhance treatment. Its aesthetic impact drives demand for cosmetics like makeup and pigments. Vitiligo Treatment Market has reached US$ 615.2 Million in 2022.
Ahammune Biosciences Pvt. Ltd., Pune-primarily based, pioneers AB1001 for early vitiligo tiers, targeting T-cell activation. Phase I trials finished in January 2023.
Applied Biology's Photocil mimics phototherapy, acquired via Jupiter Wellness in July 2022, renamed PhotoFirst after India's CDSCO approval in November 2022.
Avita Medical's RECELL® System sprays autologous cells on vitiligo lesions, submitted for FDA approval in December 2022, following preliminary approval in 2018.
Edesa Biotech advances EB06 antibody with Health Canada's Phase 2 approval in February 2023. EB06 goals autoreactive T cells via CXCL10.
In October 2022, Incyte acquired Villaris Therapeutics, gaining rights to auremolimab (VM6) for vitiligo remedy, making ready for clinical trials in 2023.
Personalized care drives the segmental vitiligo treatment market growth, meeting specific needs of patients with this form of the condition.
By Type, Vitiligo Treatment Market is divided into Segmental and Non-Segmental. Segmental vitiligo treatment is the market fastest-growing segment, offering targeted solutions for localized depigmentation. The rising awareness of its unique characteristics propels its rapid expansion. Evolving medical advancements emphasize tailored therapies, reflecting a dynamic market. The segmental vitiligo treatment market is projected to sustain growth, catering to patients' specific needs in this form of the condition.
As trends evolve and industries progress, the United States is anticipated to retain its position as a significant market leader across vitiligo treatment sectors
By Country, Global Vitiligo Treatment Market is segmented into United States, Canada, Mexico, Germany, U.K., France, Italy, Spain, Japan, China, Australia, India, Brazil, Saudi Arabia, Argentina, U.A.E, South Africa and Rest of World. The United States is set to dominate the vitiligo market in the near future. Driven by factors such as economic strength, technological advancements, and a well-established healthcare system, it is poised to hold the leading position. The country's substantial investments in diverse industries and its role as a research and development hub contribute to its projected market supremacy. With a considerable consumer base and evolving industry trends, the United States is expected to maintain its position as a primary player in the vitiligo treatment market for years to come.
This latest report “Vitiligo Treatment Market, Global Forecast by Type (Segmental, Non - Segmental), by Treatment Type (Topical Treatments , Light Therapy, Surgical Procedures, Others), by End-User (Hospitals, Ambulatory Clinics, Others), by Country (United States, Canada, Mexico, Germany, U.K., France, Italy, Spain, Japan, China, Australia, India, Brazil, Saudi Arabia, Argentina, U.A.E, South Africa and Rest of World), Vitiligo Pipe Line Drugs (ARN-4079, ATI-502, AX-1602, BOS-475, CCP-070, Cerdulatinib (RVT-502), HuABC-2, Abatacept, Topical Ruxolitinib, VLRX-001), Companies (Incyte Corporation, Bristol-Myers Squibb, Clinuvel Pharmaceuticals Ltd, Astellaspharmainc, Baxter International Inc, Pfizer and Dr. Reddy’s Laboratories Ltd)” provides a detailed analysis of Global Vitiligo Treatment Industry.
2. Canada
3. Mexico
4. Germany
5. U.K.
6. France
7. Italy
8. Spain
9. Japan
10. China
11. Australia
12. India
13. Brazil
14. Saudi Arabia
15. Argentina
16. U.A.E
17. South Africa
18. Rest of World
2. Canada
3. Mexico
4. Germany
5. U.K.
6. France
7. Italy
8. Spain
9. Japan
10. China
11. Australia
12. India
13. Brazil
14. Saudi Arabia
15. Argentina
16. U.A.E
17. South Africa
18. Rest of World
2. Non - segmental
2. Light Therapy
3. Surgical Procedures
4. Others
2. Ambulatory Clinics
3. Others
2. ATI-502
3. AX-1602
4. BOS-475
5. CCP-070
6. Cerdulatinib (RVT-502)
7. HuABC-2
8. Abatacept
9. Topical Ruxolitinib
10. VLRX-001
2. Bristol-Myers Squibb
3. Clinuvel Pharmaceuticals Ltd.
4. Astellaspharmainc
5. Baxter International Inc
6. Pfizer
7. Dr. Reddy’s Laboratories Ltd.
Vitiligo Treatment Market is growing at a CAGR of 4.96% from 2022 to 2028
The escalating global prevalence of vitiligo is a driving force behind market expansion, as an increasing number of individuals receive diagnoses. Progress in treatment alternatives, encompassing topical medications, phototherapy, and surgical interventions, empowers patients with diversified options and enhanced outcomes. Heightened cognizance of vitiligo within both medical circles and the public sphere facilitates prompt identification and intervention, propelling the need for therapeutic approaches and management tactics.Ongoing research delves into vitiligo's origins and novel treatments, advancing the market. Advocacy groups support companies, offering resources and improving accessibility. Technological advancements, like lasers and drug delivery, enhance treatment. Its aesthetic impact drives demand for cosmetics like makeup and pigments. Vitiligo Treatment Market has reached US$ 615.2 Million in 2022.
New pipeline of Vitiligo Treatment
AbbVie reiterated commitment to pores and skin ailment studies, which includes vitiligo, at EADV 2022. Glimpses on their website hinted at a RoRT inhibitor have a look at for immune problems. 2023 IIS Strategic Priorities label vitiligo as "Non-Product Only."Ahammune Biosciences Pvt. Ltd., Pune-primarily based, pioneers AB1001 for early vitiligo tiers, targeting T-cell activation. Phase I trials finished in January 2023.
Applied Biology's Photocil mimics phototherapy, acquired via Jupiter Wellness in July 2022, renamed PhotoFirst after India's CDSCO approval in November 2022.
Avita Medical's RECELL® System sprays autologous cells on vitiligo lesions, submitted for FDA approval in December 2022, following preliminary approval in 2018.
Edesa Biotech advances EB06 antibody with Health Canada's Phase 2 approval in February 2023. EB06 goals autoreactive T cells via CXCL10.
In October 2022, Incyte acquired Villaris Therapeutics, gaining rights to auremolimab (VM6) for vitiligo remedy, making ready for clinical trials in 2023.
Personalized care drives the segmental vitiligo treatment market growth, meeting specific needs of patients with this form of the condition.
By Type, Vitiligo Treatment Market is divided into Segmental and Non-Segmental. Segmental vitiligo treatment is the market fastest-growing segment, offering targeted solutions for localized depigmentation. The rising awareness of its unique characteristics propels its rapid expansion. Evolving medical advancements emphasize tailored therapies, reflecting a dynamic market. The segmental vitiligo treatment market is projected to sustain growth, catering to patients' specific needs in this form of the condition.
Topical treatments hold a prominent position in the global vitiligo industry
By Treatment Type, Vitiligo Treatment Market is segmented into Topical Treatments, Light Therapy, Surgical Procedures and Others. Topical treatments dominate the vitiligo industry due to their convenience, non-invasiveness, and efficacy in localized treatment. These encompass corticosteroids, calcineurin inhibitors, and vitamin D analogs, delivering precise outcomes. The preference for non-surgical approaches strengthens their popularity, aided by patient compliance and ease of use. Topical solutions are ideal for limited disease spread and milder interventions, while ongoing research and innovation ensure their continued leadership in addressing vitiligo's diverse severity levels.Growing demand for patient-centric care underscores ambulatory clinics' pivotal role in shaping the future of vitiligo treatment
By End User, Vitiligo Treatment Market is segmented into Hospitals, Ambulatory Clinics and Others. Ambulatory clinics rapidly dominate the vitiligo sector, offering outpatient convenience, specialized treatments, and expert consultations. This growth caters to patients seeking effective solutions without hospitalization, aligning with the demand for non-invasive and personalized medical services. This trend fosters ambulatory clinics as a trusted choice, allowing patients to maintain routines. Easy access to targeted therapies and ongoing care adds to their popularity. Evolving with technology and innovative approaches, these clinics' upward trajectory is set to continue. The surge in demand for accessible, patient-centric care highlights the vital role of ambulatory clinics in shaping the future of vitiligo treatment.As trends evolve and industries progress, the United States is anticipated to retain its position as a significant market leader across vitiligo treatment sectors
By Country, Global Vitiligo Treatment Market is segmented into United States, Canada, Mexico, Germany, U.K., France, Italy, Spain, Japan, China, Australia, India, Brazil, Saudi Arabia, Argentina, U.A.E, South Africa and Rest of World. The United States is set to dominate the vitiligo market in the near future. Driven by factors such as economic strength, technological advancements, and a well-established healthcare system, it is poised to hold the leading position. The country's substantial investments in diverse industries and its role as a research and development hub contribute to its projected market supremacy. With a considerable consumer base and evolving industry trends, the United States is expected to maintain its position as a primary player in the vitiligo treatment market for years to come.
Key Player
Incyte Corporation, Bristol-Myers Squibb, Clinuvel Pharmaceuticals Ltd, Astellaspharmainc, Baxter International Inc, Pfizer and Dr. Reddy’s Laboratories Ltd. are the some of the major companies that operate in the global vitiligo treatment market.This latest report “Vitiligo Treatment Market, Global Forecast by Type (Segmental, Non - Segmental), by Treatment Type (Topical Treatments , Light Therapy, Surgical Procedures, Others), by End-User (Hospitals, Ambulatory Clinics, Others), by Country (United States, Canada, Mexico, Germany, U.K., France, Italy, Spain, Japan, China, Australia, India, Brazil, Saudi Arabia, Argentina, U.A.E, South Africa and Rest of World), Vitiligo Pipe Line Drugs (ARN-4079, ATI-502, AX-1602, BOS-475, CCP-070, Cerdulatinib (RVT-502), HuABC-2, Abatacept, Topical Ruxolitinib, VLRX-001), Companies (Incyte Corporation, Bristol-Myers Squibb, Clinuvel Pharmaceuticals Ltd, Astellaspharmainc, Baxter International Inc, Pfizer and Dr. Reddy’s Laboratories Ltd)” provides a detailed analysis of Global Vitiligo Treatment Industry.
Country - Patient Numbers & Market has been covered from 18 viewpoints:
1. United States2. Canada
3. Mexico
4. Germany
5. U.K.
6. France
7. Italy
8. Spain
9. Japan
10. China
11. Australia
12. India
13. Brazil
14. Saudi Arabia
15. Argentina
16. U.A.E
17. South Africa
18. Rest of World
Country - Volume has been covered from 18 viewpoints:
1. United States2. Canada
3. Mexico
4. Germany
5. U.K.
6. France
7. Italy
8. Spain
9. Japan
10. China
11. Australia
12. India
13. Brazil
14. Saudi Arabia
15. Argentina
16. U.A.E
17. South Africa
18. Rest of World
Vitiligo Type - Market has been covered from 2 viewpoints:
1. Segmental2. Non - segmental
Treatment Type - Market has been covered from 4 viewpoints:
1. Topical Treatments2. Light Therapy
3. Surgical Procedures
4. Others
End User - Market has been covered from 4 viewpoints:
1. Hospitals2. Ambulatory Clinics
3. Others
Vitiligo Pipe Line Drugs market has been covered from 10 viewpoints:
1. ARN-40792. ATI-502
3. AX-1602
4. BOS-475
5. CCP-070
6. Cerdulatinib (RVT-502)
7. HuABC-2
8. Abatacept
9. Topical Ruxolitinib
10. VLRX-001
Company Insight:
- Overview
- Recent Development
- Revenue
Companies Covered:
1. Incyte Corporation2. Bristol-Myers Squibb
3. Clinuvel Pharmaceuticals Ltd.
4. Astellaspharmainc
5. Baxter International Inc
6. Pfizer
7. Dr. Reddy’s Laboratories Ltd.
Table of Contents
1. Introduction2. Research & Methodology3. Executive Summary12. Clinical Study of Vitiligo Market
4. Market Dynamics
5. Global Vitiligo Patient Numbers & Market
6. Market Share - Global Vitiligo Patient Analysis
7. Diseases Type - Global Vitiligo Market
8. Treatment Type - Global Vitiligo Market
9. End User - Global Vitiligo Market
10. Country - Vitiligo Patient Numbers & Market
11. Vitiligo Pipe Line Drugs
13. Porter’s Five Forces
14. SWOT Analysis
15. Company Analysis
List of Figures
List of Tables
Companies Mentioned
- Incyte Corporation
- Bristol-Myers Squibb
- Clinuvel Pharmaceuticals Ltd.
- Astellaspharmainc
- Baxter International Inc
- Pfizer
- Dr. Reddy’s Laboratories Ltd.
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | August 2023 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 615.2 Million |
| Forecasted Market Value ( USD | $ 822.75 Million |
| Compound Annual Growth Rate | 4.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 7 |
